TipRanks
Go Ultimate55% OFF

Compare Otsuka Holdings Co (OS1) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:OS1Otsuka Holdings CoEUR 69.00EUR 35.79B16.3250.66%Moderate BuyUnlock the DE:OS1 analyst price target with TipRanks PremiumDE:OS1Unlock the DE:OS1 top-analyst price target with TipRanks Premium
JP:4503Astellas PharmaJPY 2,569.00JPY 4.63T12.6260.69%NeutralUnlock the JP:4503 analyst price target with TipRanks PremiumDE:OS1 vs JP:4503Unlock the JP:4503 top-analyst price target with TipRanks Premium
JP:4519Chugai Pharmaceutical CoJPY 6,843.00JPY 11.23T22.290.21%Moderate BuyUnlock the JP:4519 analyst price target with TipRanks PremiumDE:OS1 vs JP:4519Unlock the JP:4519 top-analyst price target with TipRanks Premium
JP:4568Daiichi Sankyo CompanyJPY 2,892.50JPY 5.01T17.98-28.32%Strong BuyUnlock the JP:4568 analyst price target with TipRanks PremiumDE:OS1 vs JP:4568Unlock the JP:4568 top-analyst price target with TipRanks Premium
JP:4523Eisai CoJPY 5,016.00JPY 1.42T33.6610.60%―Unlock the JP:4523 analyst price target with TipRanks PremiumDE:OS1 vs JP:4523Unlock the JP:4523 top-analyst price target with TipRanks Premium
JP:4502Takeda Pharmaceutical CoJPY 6,647.00JPY 10.62T27.1656.24%Strong BuyUnlock the JP:4502 analyst price target with TipRanks PremiumDE:OS1 vs JP:4502Unlock the JP:4502 top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:OS1Otsuka Holdings Co69.0023.0050.00%
JP:4503Astellas Pharma2571.001008.6264.56%
JP:4519Chugai Pharmaceutical Co6822.00-42.30-0.62%
JP:4568Daiichi Sankyo Company2754.00-802.20-22.56%
JP:4523Eisai Co5052.00628.7914.22%
JP:4502Takeda Pharmaceutical Co6651.002639.3265.79%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts